Holen Sie sich die Stockscreener-App
11.80
4.33%
0.49
Handel nachbörslich:
11.80
Schlusskurs vom Vortag:
$11.31
Offen:
$11.41
24-Stunden-Volumen:
188.19K
Relative Volume:
0.93
Marktkapitalisierung:
$441.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.60%
1M Leistung:
+25.53%
6M Leistung:
-35.83%
1J Leistung:
-52.82%
1-Tages-Spanne:
$11.19
$12.17
1-Wochen-Bereich:
$11.05
$12.26
52-Wochen-Spanne:
$7.13
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Firmenname
Rapport Therapeutics Inc
Sektor
Branche
Telefon
857-321-8020
Adresse
1325 BOYLSTON STREET, BOSTON
Vergleichen Sie RAPP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
11.80 | 441.62M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-08 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Eingeleitet | Jefferies | Buy |
| 2024-07-02 | Eingeleitet | Stifel | Buy |
| 2024-07-02 | Eingeleitet | TD Cowen | Buy |
Rapport Therapeutics Inc Aktie (RAPP) Neueste Nachrichten
GAMMA Investing LLC Purchases 9,198 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Bank of America Corp DE Sells 12,532 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
California State Teachers Retirement System Purchases 7,886 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - MarketBeat
(RAPP) Long Term Investment Analysis - news.stocktradersdaily.com
Rapport Therapeutics management to meet with Citizens JMP - TipRanks
Deutsche Bank AG Invests $41,000 in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Stifel reiterates buy rating for Rapport Therapeutics stock By Investing.com - Investing.com Nigeria
Citizens JMP maintains positive outlook on Rapport Therapeutics stock By Investing.com - Investing.com UK
Rapport Therapeutics Completes Enrollment for Phase 2a Trial - TipRanks
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates - GlobeNewswire
Rapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical Pipeline - Nasdaq
How the (RAPP) price action is used to our Advantage - news.stocktradersdaily.com
Rapport Therapeutics to Participate in the Jefferies Global - GlobeNewswire
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference - Yahoo Finance
Rapport Therapeutics (RAPP) to Release Quarterly Earnings on Monday - Defense World
Rapport Therapeutics to Host 2025 Investor and Analyst Day - GlobeNewswire
Companies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In Growth - Yahoo Finance
Rapport Therapeutics Reports Q1 2025 Financial Results - MSN
Wells Fargo & Company MN Grows Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Barclays PLC Buys 5,634 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics, Inc. SEC 10-Q Report - TradingView
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update - The Manila Times
(RAPP) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Rapport Therapeutics (NASDAQ:RAPP) Shares Acquired by JPMorgan Chase & Co. - Defense World
Legal & General Group Plc Buys 8,614 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Acquired by Geode Capital Management LLC - Defense World
Rapport Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
When the Price of (RAPP) Talks, People Listen - news.stocktradersdaily.com
Rapport therapeutics chief scientific officer sells $81,310 of stock - Investing.com Australia
Rapport therapeutics chief scientific officer sells $81,310 of stock By Investing.com - Investing.com South Africa
KLP Kapitalforvaltning AS Purchases Shares of 1,900 Rapport Therapeutics (NASDAQ:RAPP) - Defense World
48,452 Shares in Rapport Therapeutics (NASDAQ:RAPP) Acquired by Norges Bank - Defense World
Comparing Rapport Therapeutics (RAPP) & The Competition - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at JMP Securities - Defense World
JMP Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Market Outperform Recommendation - Nasdaq
Citizens JMP sets $28 target for Rapport Therapeutics stock By Investing.com - Investing.com Canada
(RAPP) Investment Analysis - news.stocktradersdaily.com
nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Rapport Therapeutics: Too Early To Be Interesting (NASDAQ:RAPP) - Seeking Alpha
Swiss National Bank Purchases New Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analyzing Neurogene (NASDAQ:NGNE) & Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Validea Kenneth Fisher Strategy Daily Upgrade Report3/25/2025 - Nasdaq
Finanzdaten der Rapport Therapeutics Inc-Aktie (RAPP)
Es liegen keine Finanzdaten für Rapport Therapeutics Inc (RAPP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):